Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon‐like peptide‐1 secretion
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the effects of the primary human bile acid, chenodeoxycholic acid ( CDCA ), and the bile acid sequestrant ( BAS ) colesevelam, instilled into the stomach, on plasma levels of glucagon‐like peptide‐1 ( GLP ‐1), glucose‐dependent insulinotropic polypeptide, glucose, insulin, C‐peptide, glucagon, cholecystokinin and gastrin, as well as on gastric emptying, gallbladder volume, appetite and food intake. Methods: On four separate days, nine patients with type 2 diabetes, and 10 matched healthy control subjects received bolus instillations of (i) CDCA , (ii) colesevelam, (iii) CDCA + colesevelam or (iv) placebo. At baseline and for 180 min after instillation, blood was sampled. Results: In both the type 2 diabetes group and the healthy control group, CDCA elicited an increase in GLP ‐1 levels compared with colesevelam, CDCA + colesevelam and placebo, respectively (p < 0.05). The interventions did not affect plasma glucose, insulin or C‐peptide concentrations in any of the groups. CDCA elicited a small increase in plasma insulin : glucose ratio compared with colesevelam, CDCA + colesevelam and placebo in both groups. Compared with colesevelam, CDCA + colesevelam and placebo, respectively, CDCA increased glucagon and delayed gastric emptying in both groups. Conclusions: CDCA increased GLP ‐1 and glucagon secretion, and delayed gastric emptying. We speculate that bile acid‐induced activation of TGR5 on L cells increases GLP ‐1 secretion, which, in turn, may result in amplification of glucose‐stimulated insulin secretion. Furthermore our data suggest that colesevelam does not have an acute effect on GLP ‐1 secretion in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Colesevelam is now approved in the USA for treatment of type 2 diabetes and is recommended in the diabetes management guidelines [17].”
BackgroundFlint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
A G Protein-coupled Receptor Responsive to Bile Acids
Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628 · cited 2×
“Furthermore, while CDCA is the most abundant bile acid in humans, it is only a moderately potent TGR5 agonist [30].”
BackgroundIdentification of membrane-type receptor for bile acids (M-BAR)
Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., & Tanaka, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02550-0 · Cited by 993
Katsuma, S., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.139 · Cited by 789 · cited 1×
“TGR5 is expressed in enteroendocrine L cells in the intestine, and it has been shown that bile acids, via TGR5 activation and subsequent cAMP synthesis, promote glucagon-like peptide-1 (GLP-1) secretion in an enteroendocrine cell line [4].”
BackgroundKumar, D. P., Rajagopal, S., Mahavadi, S., Mirshahi, F., Grider, J. R., Murthy, K. S., & Sanyal, A. J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.104 · Cited by 206 · cited 1×
“Alternatively, CDCA could activate TGR5 receptors on the β cell directly to promote insulin secretion, as previously reported in an in vitro study [36].”
ResultOn the physiology of GIP and GLP-1
Holst, J. J. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826158 · Cited by 189 · cited 4×
“infusion of native GLP-1 is known to delay gastric emptying [6].”
BackgroundInfluentialSelf-citation
Cited by
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Puri, P., Daita, K., Joyce, A., Mirshahi, F., Santhekadur, P. K., Cazanave, S., Luketic, V. A., Siddiqui, M. S., Boyett, S., Min, H., et al. (2018) · Hepatology · doi:10.1002/hep.29359 · Cited by 426
“Upon activation of TGR5 receptors, L cells release glucagonlike peptide 1, which has pleiotropic effects in NASH including increased insulin sensitivity and promoting beta-cell function.((30-33)) Insulin resistance and the combination of increased free fatty acid delivery to the liver and increased de novo lipogenesis…”
BackgroundBile acids in glucose metabolism and insulin signalling — mechanisms and research needs
Ahmad, T. R., & Haeusler, R. A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0266-7 · Cited by 337
Bahne, E., Sun, E. W. L., Young, R. L., Hansen, M., Sonne, D. P., Hansen, J. S., Rohde, U., Liou, A. P., Jackson, M. L., de Fontgalland, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93936 · Cited by 173
Metadata
- Authors
- Hansen, M., Scheltema, M. J., Sonne, D. P., Hansen, J. S., Sperling, M., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-03-22
- Volume
- 18
- Issue
- 6
- Pages
- 571-580
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2283376353
- Cited by
- 96
- References
- 7
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon‐like peptide‐1 secretion. https://app.cochat.ai/papers/10.1111/dom.12648
- The paper
- Hansen, M., Scheltema, M. J., Sonne, D. P., Hansen, J. S., Sperling, M., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016). Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon‐like peptide‐1 secretion. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.